China Biologic Products, Inc. Form 8-K June 16, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest event Reported): June 15, 2015

CHINA BIOLOGIC PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

Delaware 001-34566 75-2308816

(State or other jurisdiction of (Commission File No.) (IRS Employer ID No.) incorporation or organization)

18th Floor, Jialong International Building 19 Chaoyang Park Road Chaoyang District, Beijing 100125 People's Republic of China (Address of Principal Executive Offices)

Edgar Filing: China Biologic Products, Inc. - Form 8-K

86-10-6698-3166
Registrant's telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

ITEM 7.01 REGULATION FD DISCLOSURE.

On June 15, 2015, China Biologic Products, Inc. (the "Company") completed an offering (the "Offering") of 3,450,000 shares of its common stock at a public offering price of \$105.00 per share, less the underwriting discounts and commissions. In the Offering, the Company sold 805,000 shares (including 105,000 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from the Company) and certain selling stockholders sold 2,645,000 shares (including 345,000 shares sold pursuant to the exercise by the underwriters of their option to purchase additional shares from such selling stockholders).

The Offering was made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission.

The information contained in this report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 16, 2015 CHINA BIOLOGIC PRODUCTS, INC.

By: /s/ David (Xiaoying) Gao David (Xiaoying) Gao Chief Executive Officer